Growth Achieved in Spherix's Health Sciences Consultin...( Phase 3 Clinical Trial on Track ...),Health

Phase 3 Clinical Trial on Track, Market Research Contracts Signed

BELTSVILLE, Md., Nov. 29 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) has recently signed contracts to provide technical and regulatory consulting services to several major consumer, food, ingredient, and pharmaceutical companies. Spherix's Health Sciences Consulting Division provides scientific and strategic support for suppliers, manufacturers, distributors, and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides.

"I am very pleased with the progress made in our Health Sciences Division," said Claire Kruger, CEO and Director of Health Sciences of Spherix. "Revenues earned through these efforts will add to our substantial cash reserve, and will be very useful moving forward."

The Company further reported that its Phase 3 clinical trial of Naturlose(R) as a treatment for Type 2 diabetes is progressing on schedule. Since moving the entire study to the United States, patient recruitment has increased and, logistically, everything is moving ahead much more efficiently. The protocol for the Company's dose ranging study has been finalized and is scheduled to begin later this year. An additional study to determine if Naturlose will work with only one dose per day is being finalized, and it is hoped that this study will begin early next year. Results from a recent trial evaluating efficacy of tagatose in toothpaste that was conducted at the University of Maryland did not show significant activity; further trials for this endpo
'/>"/>